About: Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 February 2000

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в лютому 2000 (uk) im Februar 2000 veröffentlichter wissenschaftlicher Artikel (de) wüsseschaftlicher Artikel, wo im Hornig 2000 veröffentlicht worden isch (gsw) artículu científicu espublizáu en febreru de 2000 (ast) artikull shkencor i botuar më 01 shkurt 2000 (sq) scientific article published on 01 February 2000 (en)
publication date	wds:Q73492524-FF5B4886-850E-4677-BDE2-F9198C3DC685
publication date	2000-02-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q73492524-744D2CD8-292B-4AED-9F93-5A2E2195A953
language of work or name	English
author name string	wds:Q73492524-2A8EED86-1C3F-4323-B0A8-72B31ABA423B wds:Q73492524-405D95CC-2D9A-43FA-AB43-4CA052B8F998 wds:Q73492524-7B955ED4-E7BA-487C-A572-5871933553D3 wds:Q73492524-7F8B878B-70AD-4FA1-95E4-EB852C3169C4 wds:Q73492524-9E17AAA1-2400-4C2A-9ADB-61A108120589 wds:Q73492524-BE3EC9DB-2586-4345-8D35-837EEA237D39 wds:Q73492524-C4BE033F-F4E8-4AF7-8E1B-A8E3D1FFEA71 wds:Q73492524-D8136DED-5D55-408F-AE54-2AC7C201128F wds:Q73492524-F12D7FAF-2CA3-471E-B426-2573B9FD9E86
author name string	Le Jemtel TH Sonnenblick EH Hammer A Ennezat PV Jorde UP Cukon S Infeld J Lisker J Suryadevara V
rdfs:label	Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure (en) Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure (sq) Maximally recommended doses of angiotensin-converting enzyme (nl)
skos:prefLabel	Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure (en) Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure (sq) Maximally recommended doses of angiotensin-converting enzyme (nl)
name	Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure (en) Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure (sq) Maximally recommended doses of angiotensin-converting enzyme (nl)
title	wds:Q73492524-5C8C426E-276D-4787-8C0F-585DA6A2784F
title	Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure (en)
page(s)	wds:Q73492524-6C39183E-9A03-4708-B869-268712BE729B
page(s)	844-846
instance of	wds:Q73492524-C57154CC-BBD2-44B1-ADAE-160B104A4DCE
instance of	scholarly article
main subject	wds:Q73492524-BCAF7CF2-ED35-4AC0-A0C0-8D6811F74CF0
main subject	chronic heart failure
PubMed ID	wds:Q73492524-39218A14-FA70-4048-9307-F43E0E9AFF29
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/10694521
PubMed ID	10694521
published in	wds:Q73492524-08A0DDF3-C038-4CE9-93B6-14CBB06845A6
published in	Circulation
issue	wds:Q73492524-45F0565C-008B-4956-9186-A4CFC575BD6A
volume	wds:Q73492524-225D0082-0BF9-430F-BF4D-5FDFBED9843C
issue	8
volume	101
DOI	wds:Q73492524-88503A42-D3E7-4E30-BC76-54A6ACDA6961
DOI	http://dx.doi.org/10.1161/01.CIR.101.8.844
DOI	10.1161/01.CIR.101.8.844
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q73492524
is cites work of	Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial Local renin-angiotensin systems: the unanswered questions Interactions between the sympathetic nervous system and the RAAS in heart failure Role of the ACE2/Angiotensin 1-7 Axis of the Renin-Angiotensin System in Heart Failure Treatment of heart failure with ACE inhibitors and beta-blockers: what is next? AT1-receptor antagonists? Therapeutic implications of escape from angiotensin-converting enzyme inhibition in patients with chronic heart failure Advanced glycation end products activate a chymase-dependent angiotensin II-generating pathway in diabetic complications Dual blockade of the renin-angiotensin-aldosterone system: beyond the ACE inhibitor and angiotensin-II receptor blocker combination Elastase-2, a Tissue Alternative Pathway for Angiotensin II Generation, Plays a Role in Circulatory Sympathovagal Balance in Mice Gradual reactivation over time of vascular tissue angiotensin I to angiotensin II conversion during chronic lisinopril therapy in chronic heart failure Elastase-2, an angiotensin II-generating enzyme, contributes to increased angiotensin II in resistance arteries of mice with myocardial infarction. The renin-angiotensin system in mitral regurgitation: a typical example of tissue activation The power to TRANSCEND. Early imaging in heart failure: exploring novel molecular targets Relation of aldosterone "escape" despite angiotensin-converting enzyme inhibitor administration to impaired exercise capacity in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy Is too much neurohormonal blockade harmful? Redefining the ACE-inhibitor dose-response relationship: substantial blood pressure lowering after massive doses Reduction in arterial stiffness with angiotensin II antagonist is comparable with and additive to ACE inhibition Aldosterone receptor blockade in the management of heart failure Clinical use of markers of neurohormonal activation in heart failure Blocking the RAAS at different levels: an update on the use of the direct renin inhibitors alone and in combination Prospective evaluation comparing the effects of enalapril and losartan in left ventricular remodeling after acute myocardial infarction Addition of candesartan to angiotensin converting enzyme inhibitor therapy in patients with chronic heart failure does not reduce levels of oxidative stress Valsartan in the treatment of heart attack survivors Importance of endogenous compensatory vasoactive peptides in broadening the effects of inhibitors of the renin-angiotensin system for the treatment of heart failure. Safety and efficacy of valsartan versus enalapril in heart failure patients Reactive oxygen species-targeted therapeutic interventions for atrial fibrillation. Role of the renin-angiotensin system in the pathogenesis of intimal hyperplasia: therapeutic potential for prevention of vein graft failure? Optimal strategies for preventing progression of renal disease: should angiotensin converting enzyme inhibitors and angiotensin receptor blockers be used together? The angiotensin-converting enzyme inhibitor and aspirin interaction in congestive heart failure: fear or reality? Do we need more than just powerful blood pressure reductions? New paradigms in end-organ protection Candesartan in heart failure Role of valsartan and other angiotensin receptor blocking agents in the management of cardiovascular disease Drug Interactions in Parkinson's Disease: Safety of Pharmacotherapy for Arterial Hypertension Inhibition of RAAS--when is it too much? Insufficient hypothalamic angiotensin-converting enzyme 2 is associated with hypertension in SHR rats Activation of vascular tissue angiotensin-converting enzyme (ACE) in heart failure. Effects of ACE inhibitors Chronic ACE inhibitor treatment increases angiotensin type 1 receptor binding in vivo in the dog kidney Interaction of -blockers and angiotensin receptor blockers/ACE inhibitors in heart failure Gradual reactivation of vascular angiotensin I to angiotensin II conversion during chronic ACE inhibitor therapy in patients with diabetes mellitus

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 190 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software